These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 28560458

  • 21. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati G, Terwey JH, van Krieken JH.
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [Abstract] [Full Text] [Related]

  • 22. The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.
    Meriggi F, Vermi W, Bertocchi P, Zaniboni A.
    Rev Recent Clin Trials; 2014 Sep; 9(1):8-12. PubMed ID: 24758538
    [Abstract] [Full Text] [Related]

  • 23. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
    Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J.
    J Cell Sci; 2004 Apr 15; 117(Pt 10):2037-49. PubMed ID: 15054110
    [Abstract] [Full Text] [Related]

  • 24. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer.
    De Robertis M, Loiacono L, Fusilli C, Poeta ML, Mazza T, Sanchez M, Marchionni L, Signori E, Lamorte G, Vescovi AL, Garcia-Foncillas J, Fazio VM.
    Clin Cancer Res; 2017 Jan 01; 23(1):159-170. PubMed ID: 27401248
    [Abstract] [Full Text] [Related]

  • 25. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.
    Janku F, Wheler JJ, Hong DS, Kurzrock R.
    Target Oncol; 2013 Sep 01; 8(3):183-188. PubMed ID: 23400451
    [Abstract] [Full Text] [Related]

  • 26. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K, Ciuleanu TE, Vrbanec D, Marton E, Messinger D, Liegl-Atzwanger B, Wrba F, Knittelfelder R, Lindner E, Zielinski CC, Streubel B, Brodowicz T.
    Clin Colorectal Cancer; 2015 Jun 01; 14(2):91-8. PubMed ID: 25666295
    [Abstract] [Full Text] [Related]

  • 27. Alteration of the EphA2/Ephrin-A signaling axis in psoriatic epidermis.
    Gordon K, Kochkodan JJ, Blatt H, Lin SY, Kaplan N, Johnston A, Swindell WR, Hoover P, Schlosser BJ, Elder JT, Gudjonsson JE, Getsios S.
    J Invest Dermatol; 2013 Mar 01; 133(3):712-722. PubMed ID: 23190894
    [Abstract] [Full Text] [Related]

  • 28. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 01; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 29. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
    Yang NY, Fernandez C, Richter M, Xiao Z, Valencia F, Tice DA, Pasquale EB.
    Cell Signal; 2011 Jan 01; 23(1):201-12. PubMed ID: 20837138
    [Abstract] [Full Text] [Related]

  • 30. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer.
    Lindner AU, Carberry S, Monsefi N, Barat A, Salvucci M, O'Byrne R, Zanella ER, Cremona M, Hennessy BT, Bertotti A, Trusolino L, Prehn JHM.
    Int J Cancer; 2020 Nov 15; 147(10):2891-2901. PubMed ID: 32700762
    [Abstract] [Full Text] [Related]

  • 31. Truncated EphA2 likely potentiates cell adhesion via integrins as well as infiltration and/or lodgment of a monocyte/macrophage cell line in the red pulp and marginal zone of the mouse spleen, where ephrin-A1 is prominently expressed in the vasculature.
    Konda N, Saeki N, Nishino S, Ogawa K.
    Histochem Cell Biol; 2017 Mar 15; 147(3):317-339. PubMed ID: 27665280
    [Abstract] [Full Text] [Related]

  • 32. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
    Alcantara KMM, Malapit JRP, Yu RTD, Garrido JAMG, Rigor JPT, Angeles AKJ, Cutiongco-de la Paz EM, Garcia RL.
    Cells; 2019 Dec 03; 8(12):. PubMed ID: 31816869
    [Abstract] [Full Text] [Related]

  • 33. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F.
    Oncotarget; 2016 Feb 23; 7(8):9309-21. PubMed ID: 26824184
    [Abstract] [Full Text] [Related]

  • 34. Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer.
    Efazat G, Novak M, Kaminskyy VO, De Petris L, Kanter L, Juntti T, Bergman P, Zhivotovsky B, Lewensohn R, Hååg P, Viktorsson K.
    Oncotarget; 2016 Sep 13; 7(37):60332-60347. PubMed ID: 27533087
    [Abstract] [Full Text] [Related]

  • 35. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
    Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, Wu L, Dhariwal J, Mohammed SI.
    Clin Cancer Res; 2006 Jan 15; 12(2):353-60. PubMed ID: 16428472
    [Abstract] [Full Text] [Related]

  • 36. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis.
    Dohn M, Jiang J, Chen X.
    Oncogene; 2001 Oct 04; 20(45):6503-15. PubMed ID: 11641774
    [Abstract] [Full Text] [Related]

  • 37. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
    Bahrami A, Hassanian SM, ShahidSales S, Farjami Z, Hasanzadeh M, Anvari K, Aledavood A, Maftouh M, Ferns GA, Khazaei M, Avan A.
    J Cell Physiol; 2018 Mar 04; 233(3):2058-2066. PubMed ID: 28262927
    [Abstract] [Full Text] [Related]

  • 38. EphA2 Transmembrane Domain Is Uniquely Required for Keratinocyte Migration by Regulating Ephrin-A1 Levels.
    Ventrella R, Kaplan N, Hoover P, Perez White BE, Lavker RM, Getsios S.
    J Invest Dermatol; 2018 Oct 04; 138(10):2133-2143. PubMed ID: 29705292
    [Abstract] [Full Text] [Related]

  • 39. Restriction of receptor movement alters cellular response: physical force sensing by EphA2.
    Salaita K, Nair PM, Petit RS, Neve RM, Das D, Gray JW, Groves JT.
    Science; 2010 Mar 12; 327(5971):1380-5. PubMed ID: 20223987
    [Abstract] [Full Text] [Related]

  • 40. Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer.
    Kim D, Hong YS, Kim JE, Kim KP, Lee JL, Chun SM, Kim J, Jang SJ, Kim TW.
    Cancer Res Treat; 2017 Jan 12; 49(1):37-43. PubMed ID: 27121720
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.